CELLTECH
CELLTECH's Overview
Celltech Group plc was a prominent British biotechnology company, one of the largest in Europe during its time. Founded in 1980, it specialized in the research, development, and commercialization of antibody-based therapeutics and other biopharmaceuticals, with a strong focus on immunology and oncology. Key products developed or in its pipeline included treatments for Crohn's disease, rheumatoid arthritis, and cancer. In 2004, Celltech was acquired by the Belgian biopharmaceutical company UCB S.A. for approximately £1.53 billion, integrating Celltech's innovative antibody platform and research capabilities into UCB's operations. This acquisition significantly bolstered UCB's pipeline, particularly with drugs like Cimzia (certolizumab pegol).
Where is CELLTECH's Headquarters?
HQ Function
The Slough headquarters served as the central hub for global operations, including cutting-edge research and development in antibody engineering, corporate administration, strategic planning, and clinical development oversight.
Notable Features:
The facility housed advanced research laboratories, pilot manufacturing capabilities for biopharmaceuticals, and corporate offices. Its location on Bath Road placed it within a prominent commercial corridor.
Work Culture:
As a leading R&D-focused biotechnology firm, Celltech's work culture was characterized by scientific innovation, collaboration between multidisciplinary teams, a drive for therapeutic breakthroughs, and a fast-paced environment typical of the biotech industry.
HQ Significance:
The Slough headquarters was instrumental in Celltech's growth and establishment as a major player in the European biotechnology landscape. It was the nerve center for the development of key antibody technologies and therapeutic candidates that formed the basis of its acquisition by UCB.
Values Reflected in HQ: The headquarters likely reflected Celltech's core values of scientific excellence, innovation in drug discovery (particularly antibody engineering), and a commitment to developing treatments for serious diseases.
Location:
Prior to its acquisition by UCB in 2004, Celltech Group plc had a significant global presence, primarily centered in Europe (UK) and North America (USA). Its operations encompassed research and development in multiple specialized sites, manufacturing capabilities for clinical and early commercial supply, and growing commercial operations in key pharmaceutical markets. The company actively pursued international partnerships to expand the reach of its therapeutic pipeline.
Street Address:
216 Bath Road
City:
Slough
State/Province:
Berkshire
Country:
United Kingdom
CELLTECH's Global Presence
Cambridge, United Kingdom
Address: Granta Park, Great Abington, Cambridge, CB21 6GS (Example of a typical address in the science park)
To leverage the Cambridge biotech cluster's expertise, foster collaborations, and attract top scientific talent for pioneering research in immunology and oncology.
Bothell, Washington, USA
Address: Specific street address not readily available (Post-acquisition of Darwin Molecular Corp.)
To establish a significant R&D presence in the prominent US West Coast biotechnology sector, facilitating access to US-based research talent, technology, and collaborations.
Wayne, Pennsylvania, USA
Address: Specific street address not readily available (Former US commercial headquarters)
To manage and expand Celltech's commercial footprint within the crucial United States pharmaceutical market.
Buying Intent Signals for CELLTECH
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of CELLTECH
As of April 2025, CELLTECH' leadership includes:
Investors of CELLTECH
CELLTECH has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Celltech Group plc was acquired by UCB in 2004 and ceased to operate as an independent entity. Therefore, there are no executive new hires or exits for Celltech Group plc in the last 12 months. The leadership was integrated into UCB or moved to other ventures at the time of acquisition. The structures below are for illustrative purposes only.
Departures
New Appointments:
Technology (Tech Stack) used by CELLTECH
Discover the tools CELLTECH uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CELLTECH Email Formats and Examples
As Celltech Group plc was acquired in 2004, its email system is no longer active. During its operation, corporate email formats in the UK commonly followed patterns such as [first_initial][last_name]@[companydomain.co.uk] or [first_name].[last_name]@[companydomain.co.uk]. The domain would likely have been 'celltech.co.uk' or 'celltech.com'.
[first_initial][last]@celltech.co.uk (Hypothetical)
Format
pfellner@celltech.co.uk (Hypothetical example using former CEO)
Example
N/A (Company Acquired)%
Success rate
News and media
BBC News • May 19, 2004
Celltech agrees to £1.5bn UCB bid
UK biotechnology firm Celltech agreed to a £1.53bn ($2.7bn) takeover by Belgian rival UCB. The deal marked a significant consolidation in the European biotech sector and promised to create a new biopharmaceutical leader by combining UCB's strength in small molecule drugs with Celltech's expertise in antibody-based therapies....more
The Guardian • October 28, 2003
Celltech chief banks £500,000 bonus (Historical Context)
An older news piece reflecting on executive remuneration at Celltech, providing historical context on the company's operations and financial status prior to its acquisition. Such articles highlighted the company's performance and leadership activities during its peak....more
UCB Pharma Communications • Ongoing (Legacy)
UCB Continues to Advance Immunology Pipeline with Legacy Celltech Innovations
News from UCB often highlights advancements in its immunology portfolio, which includes products like Cimzia® (certolizumab pegol), a successful anti-TNF biologic that originated from Celltech's research programs. This showcases the enduring impact of Celltech's scientific contributions within UCB....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including CELLTECH, are just a search away.